Primary Progressive Multiple Sclerosis (PPMS) (DBCOND0145062)

Identifiers

Synonyms
Multiple Sclerosis (MS) Primary Progressive / Primary Multiple Sclerosis, Progressive / Primary Progressive MS / Multiple Sclerosis, Primary Progressive / Primary-progressive Multiple Sclerosis / Primary Progressive Multiple Sclerosis / Primary progressive multiple sclerosis (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Ocrelizumab
A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT04705610
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculographyNo drug interventionsotherNot Availablecompleted
NCT05177523
Imaging the Interplay Between Axonal Damage and Repair in Multiple SclerosisNo drug interventionsNot AvailableNot Availablerecruiting
NCT01804647
Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis DiseaseNo drug interventionsNot AvailableNot Availablecompleted
NCT01848327
Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple SclerosisNo drug interventionstreatmentNot Availablecompleted
NCT06436131
The Effects of In-phase Bilateral Exercise in People with Progressive Multiple SclerosisNo drug interventionstreatmentNot Availablecompleted
NCT02305264
Imaging of Intracerebral Inflammation in MSdiagnosticNot Availablecompleted
NCT06526364
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)No drug interventionsNot AvailableNot Availablenot_yet_recruiting
NCT05359653
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapytreatment1 / 2recruiting
NCT05663853
An Observational Biomarker Study in Multiple Sclerosis (MS) PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT01433497
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosistreatment3completed
NCT01982942
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosistreatment2completed
NCT04918225
Motor Asymmetry in Progressive Multiple Sclerosis PatientsNo drug interventionsNot AvailableNot Availablerecruiting
NCT03679468
Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive RehabilitationNo drug interventionsotherNot Availablecompleted
NCT02506751
Open-label Study of Liothyronine in MStreatment1completed
NCT04035005
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosistreatment3recruiting
NCT02688985
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)treatment3completed
NCT06138132
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosistreatment1recruiting
NCT05122559
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosistreatment2recruiting
NCT05204459
MS-ResearchBiomarkerSNo drug interventionsNot AvailableNot Availablerecruiting
NCT01194570
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosistreatment3completed
NCT04544449
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosistreatment3active_not_recruiting
NCT01917019
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosistreatment3completed
NCT02913157
Hydroxychloroquine in Primary Progressive Multiple Sclerosistreatment2completed
NCT03455582
Cognition Evolution and MRI Markers in PPMS Patients on 2 YearsNo drug interventionsdiagnosticNot Availablerecruiting
NCT05385731
MUSCLE - Nordic Walking in MUltiple SCLErosisNo drug interventionstreatmentNot Availablenot_yet_recruiting
NCT06384976
A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNo drug interventionstreatment2not_yet_recruiting
NCT02988401
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosistreatment1 / 2completed
NCT04545372
Aerobic Exercises for Multiple SclerosisNo drug interventionstreatmentNot Availablecompleted
NCT05496881
Exercise Effects in Multiple SclerosisNo drug interventionssupportive_careNot Availablerecruiting
NCT04550650
Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS PatientsNo drug interventionstreatmentNot Availablecompleted
NCT03424538
The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis PatientsNo drug interventionstreatmentNot Availablecompleted
NCT02606929
Use of Well Known Drugs for New Destination - MS Improvement (MSNT)Not Available0temporarily_not_available
NCT02632591
Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatmenttreatment1completed
NCT05974839
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)No drug interventionsNot AvailableNot Availablecompleted
NCT03094364
Video Game-based Therapy for Arm Weakness In Progressive Multiple SclerosisNo drug interventionstreatmentNot Availablecompleted
NCT02549703
Mitochondrial Dysfunction and Disease ProgressionNo drug interventionsNot AvailableNot Availablecompleted
NCT03783416
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple SclerosisNo drug interventionsother1recruiting
NCT03691077
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714treatment3recruiting
NCT03562975
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With OcrevusNot AvailableNot Availableactive_not_recruiting
NCT03493841
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosistreatment1completed
NCT05229861
The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMSNo drug interventionstreatmentNot Availableunknown_status
NCT01950234
ACTH in Progressive Forms of MStreatment2terminated
NCT01854359
Idebenone for Primary Progressive Multiple Sclerosistreatment1 / 2completed
NCT01191996
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple SclerosisNo drug interventionstreatment1 / 2completed
NCT05974852
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMSNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT05349474
Metformin Treatment in Progressive Multiple Sclerosistreatment0recruiting
NCT04943289
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple SclerosisNo drug interventionstreatment1recruiting
NCT04458051
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)treatment3recruiting
NCT04688788
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosistreatment3active_not_recruiting
NCT04634994
Novel Assessment of Synaptic Density in Progressive MSNo drug interventionsdiagnostic0unknown_status
NCT05029609
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MStreatment1withdrawn
NCT03362294
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMSNo drug interventionstreatment2active_not_recruiting
NCT03283826
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisNo drug interventionstreatment1 / 2terminated
NCT02253264
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patientstreatment1completed
NCT01466114
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognitiontreatment2unknown_status
NCT04977622
Gray Matter Demyelination in Primary Progressive MS at 7TNo drug interventionsNot AvailableNot Availablerecruiting
NCT05232825
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosistreatment3active_not_recruiting
NCT05893225
Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegenerationtreatment2recruiting
NCT02959658
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosistreatment2completed
NCT02284568
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebotreatment2completed
NCT02273635
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MStreatment1 / 2unknown_status
NCT02208050
A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MStreatment4completed
NCT02016222
Tear Analysis in the Diagnosis of Multiple SclerosisNo drug interventionsdiagnosticNot Availablecompleted
NCT01776060
Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT01077466
Natalizumab Treatment of Progressive Multiple Sclerosistreatment2completed
NCT00950248
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)treatment1 / 2completed
NCT00731692
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.treatment3terminated
NCT01779934
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosistreatment3completed